Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
- PMID: 29341281
- DOI: 10.1111/apt.14480
Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
Comment in
-
Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.Aliment Pharmacol Ther. 2018 Feb;47(4):540-541. doi: 10.1111/apt.14486. Aliment Pharmacol Ther. 2018. PMID: 29341277 No abstract available.
Comment on
-
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.Aliment Pharmacol Ther. 2018 Feb;47(4):454-465. doi: 10.1111/apt.14449. Epub 2017 Dec 4. Aliment Pharmacol Ther. 2018. PMID: 29205421
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical